PERTH, Australia – With another FDA approval in hand for its regenerative tissue portfolio, Brisbane, Australia-based Admedus Ltd. said it expects to become profitable in the next 12 to 18 months. The FDA cleared Vascucel for marketing on Oct. 17, and the company expects to launch the collagen scaffold for repairing vascular tissue in November.
PERTH, Australia – With another FDA approval in hand for its regenerative tissue portfolio, Brisbane, Australia-based Admedus Ltd. said it expects to become profitable in the next 12 to 18 months. The FDA cleared Vascucel for marketing on Oct. 17, and the company expects to launch the collagen scaffold for repairing vascular tissue in November.
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country.
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country.
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
PERTH, Australia – The pharma and medical device industry praised the Australian government on new reforms announced late last week that increase the pathways for marketing approval for drugs and devices and reduce regulatory red tape and redundancies.
